Kristian Lundberg
The Houston-based firm closes its fourth institutional fund at hard cap.
The opportunity fund will invest alongside the firm's flagship vehicle.
The Los Angeles-based firm nearly doubles size of previous fund.
The Paris-based firm will target middle-market European technology companies.
The New York-based biotech VC closes $120m shy of initial target.
The Menlo Park-based firm will target early-stage biotech companies.
The San Francisco-based firm will focus on early-stage consumer and retail brands.
The Los Angeles-based firm more than doubles size of predecessor vehicle.
The European biotech fund exceeds target size by €32m.
The firm's inaugural fund will invest in early-stage Israeli startups.